Benveniste R, Frohman L A, Rabinowitz D
Endocrinology. 1975 Jul;97(1):20-9. doi: 10.1210/endo-97-1-20.
Purified preparations of human luteinizing hormone (hLH), Hartree IRC-2, and NIH LER-960, have been examined after gel filtration of unlabelled and iodinated hormone. Several peaks of radioactivity were observed corresponding to dimeric (peak I), monomeric (peak II), and sub-unit (peak III) lLH forms. The immunologic and receptor activities of each fraction have been evaluated, Receptor activity was found in peaks I and II but not in peak III. Within peak II all fractions were not equally active in the receptor assay, and maximum activity appeared to correspond to molecules with elution characteristics similar to the unlabelled molecule. All fractions of peak II were immunologically active when tested against rabbit anti-hCG in excess. Two immunoassay systems with improved specificity for hLH and hLH-alpha, respectively, have been employed to show the presence of alpha subunit in one of the hLH preparations. These data have relevance with respect to testing of immuno and receptor potencies of hLH preparations.
对纯化的人促黄体生成素(hLH)制剂、哈特里IRC - 2和美国国立卫生研究院LER - 960进行了未标记和碘化激素的凝胶过滤分析。观察到几个放射性峰,分别对应二聚体(峰I)、单体(峰II)和亚基(峰III)形式的促黄体生成素。对每个组分的免疫活性和受体活性进行了评估,发现峰I和峰II有受体活性,峰III没有。在峰II内,所有组分在受体测定中的活性并不相同,最大活性似乎对应于洗脱特性与未标记分子相似的分子。当用过量的兔抗人绒毛膜促性腺激素(hCG)检测时,峰II的所有组分都具有免疫活性。分别采用了两种对hLH和hLH-α特异性有所提高的免疫测定系统,以显示其中一种hLH制剂中存在α亚基。这些数据对于检测hLH制剂的免疫和受体效力具有重要意义。